AbbVie Discontinues Development of TNFα-Targeted ADC ABBV-154 Due to Unfavorable Benefit-Risk Profile

On April 27, according to foreign media reports, AbbVie announced in its Q1 2023 earnings call that it would terminate the development plan for the TNFα ADC ABBV-154 project.

ABBV-154 consists of adalimumab targeting tumor necrosis factor α (TNFα) and a novel glucocorticoid receptor modulator (GRM). It delivers the glucocorticoid receptor modulator directly to activated immune cells expressing TNFα, aiming to regulate TNF-mediated inflammation-related pathways and reduce systemic inflammatory levels. Previously, AbbVie planned to develop ABBV-154 for indications including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), and Crohn's disease (CD).

ABBV-154 Structure (Source: See reference source)

However, AbbVie disclosed in the third quarter of 2022 that although ABBV-154 showed some efficacy in RA patients, it was decided to abandon the development of this indication after comprehensive consideration, focusing on the development of PMR and CD indications.

ABBV-154 Development Progress (Source: AbbVie Official Website)

Regarding the discontinuation of the ABBV-154 project development this time, Thomas Hudson, Senior Vice President and Chief Scientific Officer of AbbVie's R&D Department, stated: "Although ABBV-154 has shown some efficacy, we have also observed changes in biomarkers consistent with higher-dose systemic steroid exposure. The benefit-risk ratio is not sufficient to differentiate ABBV-154 from other available treatments."

Reference Source:

Merck's Oral PCSK9 Inhibitor and Nurix's BTK Degrader Among ACS First Disclosures - Drug Hunter

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reprint, please leave a message to the WeChat Official Account backend or send a message, and specify the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Reader Survey Questionnaire

Thank you for your companionship. Looking forward to your feedback.

Scan the QR code to provide valuable suggestions